Benzinga | Apr 1, 2021 09:37AM EDT

Meridian Bioscience Announces FDA Submission For New Curian Campy Assay

Meridian Bioscience, Inc. (NASDAQ:VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Company's new Curian(r) Campy assay. This assay is one of many assays in the pipeline that expands the Curian(r) menu, continuing Meridian's leadership in the gastrointestinal disease and lateral flow testing market.